Advancing treatment options for influenza: Challenges with the human influenza challenge

Journal of Infectious Diseases

Volumn 211, Issue 7, 2015, Pages 1033-1035

  Fry, Alicia M ^a   Zhong, Weimin ^a   Gubareva, Larisa V ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

M2 ECTODOMAIN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; OSELTAMIVIR; PLACEBO; PROTEIN ANTIBODY; PROTEIN INHIBITOR; PROTEIN M2; PROTEIN M2 INHIBITOR; SIALIDASE INHIBITOR; TCN 032; UNCLASSIFIED DRUG; IMMUNOLOGIC FACTOR;

2009 H1N1 INFLUENZA; AVIAN INFLUENZA; DRUG EFFICACY; EDITORIAL; FEVER; HUMAN; IMMUNOCOMPROMISED PATIENT; INFLUENZA; INFLUENZA A (H1N1); INFLUENZA A (H3N2); INFLUENZA VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEROCONVERSION; SPANISH INFLUENZA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS TITRATION; FEMALE; IMMUNOLOGY; INFLUENZA A VIRUS (H3N2); INFLUENZA, HUMAN; MALE;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MALE; OSELTAMIVIR;

EID: 84927740422     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu543     Document Type: Editorial

References (22)

1. Muthuri SG, Venkatesan S, Myles PR, et al. Effectiveness of neuraminidase inhibitors in reducing mortality in hospitalized influenza A(H1N1)pdm09 patients: an individual participant data meta-analysis. Lancet Respiratory Med 2014; 2:395-404.
2. Hayden F, Cao B. Therapy of H7N9 pneumonia: current perspectives. Exper Rev Anti Infect Ther 2013; 11:1123-6.
3. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis 2015; 211:80-90.
4. Clinicaltrials.gov. https://clinicaltrials.gov/ct2/results?term=%22monoclonal+antibodies%22 +and+%22influenza%22&Search=Search. Accessed 19 September 2014.
5. Ramos EL, Mitcham JL, Koller TD, et al. Efficacy and safety of treatment with an anti-M2e monoclonal antibody in experimental human influenza. J Infect Dis 2015; 211:1038-44.
6. Schotsaert M, De Filette M, Fiers W, Saelens X. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. Expert Rev Vaccines 2009; 8:499-508.
7. Zebedee SL, Lamb RA. Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions. J Virol 1988; 62:2762-72.
8. Liu W, Zou P, Chen Y-H. Monoclonal antibodies recognizing EVETPIRN epitope of influenza A virus M2 protein could protect mice from lethal influenza A virus challenge. Immunol Lett 2004; 93:131-6.
9. Zharikova D, Mozdzanowska K, Feng J, Zhang M, Gerhard W. Influenza type A virus escape mutants emerge in vivo in the presence of antibodies to the ectodomain of matrix protein 2. J Virol 2005; 79: 6644-54.
10. Fu T-M, Freed DC, Horton MS, et al. Characterization of four monoclonal antibodies against M2 ectodomain of influenza A virus. Virology 2009; 385:218-26.
11. Grandea AG III, Olsen OA, Cox TC, et al. Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses. Proc Natl Acad Sci USA 2010; 107: 12658-63.
12. Wang R, Song A, Levin J, et al. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. Antiviral Res 2008; 80:168-77.
13. Beerli RR, Bauer M, Schmitz N, et al. Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol J 2009; 6:224.
14. Treanor JJ, Tierney EL, Zebedee SL, Lamb RA, Murphy BR. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J Virol 1990; 64:1375-7.
15. Jegerlehner A, Schmitz N, Storni T, Bachmann MF. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunology 2004; 172: 5598-605.
16. Lamb RA, Zebedee SL, Richardson CD. Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface. Cell 1985; 40:627-33.
17. El Bakkouri K, Descamps F, De Filette M, et al. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immun 2011; 186:1022-31.
18. Heinen PP, Rijsewijk FA, de Boer-Luijtze EA, Bianchi AT. Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus. J Gen Virol 2002; 83:1851-9.
19. Khurana S, Wu J, Dimitrova M, et al. DNA priming prior to inactivated influenza A (H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults. J Infect Dis 2013; 208: 413-7.
20. Hayden F. Experimental human influenza: observations from studies of influenza antivirals. Antivir Ther 2012; 17:133-41.
21. Wilkinson TM, Li CK, Chui CSC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med 2012; 18:274-81.
22. Hayden FG, Treanor JJ, Betts RF, et al. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275:295-9.